{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:12:07Z","timestamp":1778825527507,"version":"3.51.4"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abrocitinib, a Janus kinase (JAK) inhibitor approved for moderate-to-severe atopic dermatitis (AD), has demonstrated efficacy at 100 mg in randomized controlled trials. However, real-world data on 200 mg initiation in Chinese patients remain scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of initiating abrocitinib at 200 mg in Chinese adults with moderate-to-severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 20 patients with moderate-to-severe AD treated with abrocitinib. Patients were stratified into Group A (n=7, initiated at 200 mg, tapered to 100 mg if EASI-75 or \u22654-point PP-NRS reduction was achieved by week 12) and Group B (n=13, initiated at 100 mg, escalated to 200 mg if targets were not met). Primary outcomes included Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), Peak Pruritus Numeric Rating Scale (PP-NRS), and Dermatology Life Quality Index (DLQI). Adverse events (AEs) were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both groups showed significant reductions in all outcome measures at weeks 4, 12, and 24. Baseline DLQI was significantly higher in Group A (22.0 vs. 18.0, P &amp;lt; 0.001). At week 4, Group A showed superior PP-NRS improvement (P\u00a0=\u00a00.019). By week 12, Group A achieved significantly higher rates of EASI &amp;lt; 5 (57.14% vs. 0%, P &amp;lt; 0.01) and IGA 0\/1 (85.71% vs. 7.69%, P &amp;lt; 0.01). Notably, 50% of patients had failed prior systemic therapies, including 85.7% in Group A, reflecting the refractory nature of the cohort. At week 24, Group A maintained superiority in EASI and PP-NRS (P &amp;lt; 0.05), while EASI-75 response exceeded 90% in both groups. AEs were comparable between groups (71.43% vs. 61.54%), with no serious events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 200 mg initiation strategy offers rapid and sustained disease control, particularly for patients with high baseline disease activity and severe quality of life impairment. The 100 mg strategy achieves favorable outcomes by week 24 for those with milder burden. These findings support personalized dosing, though larger prospective studies are warranted to confirm results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1789298","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:34Z","timestamp":1778823754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness and safety of 200 mg abrocitinib initiation in Chinese adults with moderate-to-severe atopic dermatitis: a retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Peilin","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]},{"name":"Department of Dermatology, The Affiliated Hospital, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judan","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-7020-6912-3.00017-3","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Dermato-Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04635.x","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023061","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update","volume":"160","author":"Drucker","year":"2024","journal-title":"JAMA Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3751","article-title":"Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies","volume":"101","author":"De Bruin-Weller","year":"2021","journal-title":"Acta Dermato-Venereol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16549","article-title":"The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan","volume":"49","author":"Hagino","year":"2022","journal-title":"J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicenter, double-blind, randomized, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet (Lond Engl)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, multicenter phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet (Lond Engl)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","article-title":"The U.K. Working Party's diagnostic criteria for atopic dermatitis. III. Independent hospital validation","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatol (Basel Switzerl)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet (Lond Engl)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2010.22.2.125","article-title":"Abrocitinib versus aplacebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s40257-025-00997-x","article-title":"Real-world evidence of effectiveness and safety of abrocitinib, baricitinib and upadacitinib in atopic dermatitis: a systematic review and meta-analysis","volume":"27","author":"R\u00f8nnstad","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1658843","article-title":"Comparative real-world effectiveness and safety of biologics and JAK inhibitors in atopic dermatitis: short- and medium-to-long-term analysis from a regional healthcare network in southern Spain","volume":"12","author":"Prados-Carmona","year":"2025","journal-title":"Front Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-026-01679-0","article-title":"Real-world effectiveness and safety of abrocitinib in patients with atopic dermatitis: a 16-week single-center retrospective cohort study compared with upadacitinib and baricitinib","volume":"16","author":"Gwag","year":"2026","journal-title":"Dermatol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1639932","article-title":"Comparative short-term efficacy of Janus kinase 1 inhibitors and anti-interleukin-13 antibodies in atopic dermatitis: a retrospective cohort analysis based on real-world data","volume":"16","author":"Sato","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19581","article-title":"Upadacitinib treatment in a real-world difficult-to-treat atopic dermatitis patient cohort","volume":"38","author":"Schl\u00f6sser","year":"2024","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19378","article-title":"Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis","volume":"37","author":"Olydam","year":"2023","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/all.16495","article-title":"Real-world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: a single-center prospective study","volume":"80","author":"Li","year":"2025","journal-title":"Allergy"},{"key":"B23","article-title":"Switching between JAK inhibitors in patients with atopic dermatitis: unanswered questions in daily clinical practice","volume":"31","author":"Mastraftsi","year":"2023","journal-title":"Acta Dermatovenerol Croatica: ADC"},{"key":"B24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1684\/ejd.2023.4581","article-title":"Successful treatment of atopic dermatitis by switching from upadacitinib to abrocitinib: a case report","volume":"33","author":"Tsai","year":"2023","journal-title":"Eur J Dermatol: EJD"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1341632","article-title":"Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1789298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:34Z","timestamp":1778823754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1789298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2026.1789298"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1789298","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1789298"}}